Free Trial
OTCMKTS:AMBBY

Ambu A/S (AMBBY) Stock Price, News & Analysis

Ambu A/S logo
$15.80 +0.20 (+1.28%)
(As of 11/22/2024 10:46 AM ET)

About Ambu A/S Stock (OTCMKTS:AMBBY)

Key Stats

Today's Range
$15.80
$15.80
50-Day Range
$15.60
$19.60
52-Week Range
$13.30
$22.65
Volume
600 shs
Average Volume
313 shs
Market Capitalization
$3.71 billion
P/E Ratio
131.67
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers extrication collars, CPR breathing barriers, video laryngoscopes, and training manikins. The company was founded in 1937 and is headquartered in Ballerup, Denmark.

Receive AMBBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ambu A/S and its competitors with MarketBeat's FREE daily newsletter.

AMBBY Stock News Headlines

Ambu A/S Reports Strong Growth and Strategic Advancements
Ambu A/S (AMBFF) Q4 2024 Earnings Call Transcript
This Bull Market Indicator called NVDA at $116
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
Ambu AS Class B AMBU B
See More Headlines

AMBBY Stock Analysis - Frequently Asked Questions

Ambu A/S's stock was trading at $15.30 on January 1st, 2024. Since then, AMBBY stock has increased by 3.3% and is now trading at $15.80.
View the best growth stocks for 2024 here
.

Ambu A/S (OTCMKTS:AMBBY) released its quarterly earnings data on Friday, August, 30th. The company reported $0.07 earnings per share for the quarter. The company earned $199.56 million during the quarter. Ambu A/S had a net margin of 4.30% and a trailing twelve-month return on equity of 4.09%.

Shares of AMBBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
8/30/2024
Today
11/23/2024
Ex-Dividend for 12/23 Dividend
12/06/2024
Dividend Payable
12/23/2024
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Holding & other investment offices
Sub-Industry
N/A
Current Symbol
OTCMKTS:AMBBY
Previous Symbol
OTCMKTS:AMBBY
CIK
N/A
Fax
N/A
Employees
4,400
Year Founded
N/A

Profitability

Net Income
$34.17 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$783.76 million

Miscellaneous

Free Float
N/A
Market Cap
$3.71 billion
Optionable
Not Optionable
Beta
N/A
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (OTCMKTS:AMBBY) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners